Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Operating Expenses: 2010-2024

Historic Operating Expenses for Altimmune (ALT) over the last 15 years, with Dec 2024 value amounting to $103.2 million.

  • Altimmune's Operating Expenses fell 15.78% to $20.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.5 million, marking a year-over-year decrease of 19.20%. This contributed to the annual value of $103.2 million for FY2024, which is 7.10% up from last year.
  • According to the latest figures from FY2024, Altimmune's Operating Expenses is $103.2 million, which was up 7.10% from $96.4 million recorded in FY2023.
  • Altimmune's 5-year Operating Expenses high stood at $103.2 million for FY2024, and its period low was $63.0 million during FY2020.
  • Moreover, its 3-year median value for Operating Expenses was $96.4 million (2023), whereas its average is $95.7 million.
  • In the last 5 years, Altimmune's Operating Expenses spiked by 130.99% in 2020 and then dropped by 13.47% in 2022.
  • Over the past 5 years, Altimmune's Operating Expenses (Yearly) stood at $63.0 million in 2020, then skyrocketed by 60.87% to $101.3 million in 2021, then decreased by 13.47% to $87.7 million in 2022, then rose by 9.90% to $96.4 million in 2023, then grew by 7.10% to $103.2 million in 2024.